UroGen Pharma Ltd Cash Flow Conversion Efficiency
UroGen Pharma Ltd cash flow conversion efficiency. Based on the latest financial reports, UroGen Pharma Ltd (URGN) has a cash flow conversion efficiency ratio of 0.249x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-33.01 Million) by net assets ($-132.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of UroGen Pharma Ltd (2013–2025)
Cash flow conversion efficiency of UroGen Pharma Ltd from 2013 to 2025. This chart illustrates how UroGen Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View URGN live share price for real-time trading data and today's change.
UroGen Pharma Ltd Cash Flow Conversion Ratio Explained
UroGen Pharma Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
UroGen Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of UroGen Pharma Ltd ranked by their cash flow conversion efficiency. Also see UroGen Pharma Ltd market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Noposion Agrochemicals Co Ltd
SHE:002215
|
-0.058x |
|
OSK Holdings Bhd
KLSE:5053
|
-0.007x |
|
Pursuit Attractions and Hospitality, Inc.
NYSE:PRSU
|
0.030x |
|
Taiwan Cogeneration Corp
TW:8926
|
-0.003x |
|
WIZZ AIR HLDG.UNSP.ADR/4
F:WI20
|
N/A |
|
Xinxiang Richful Lube Additive Co. Ltd
SHE:300910
|
0.052x |
|
Jungheinrich AG O.N.VZO
XETRA:JUN3
|
0.146x |
|
VA Tech Wabag Limited
NSE:WABAG
|
-0.021x |
Annual Cash Flow Conversion Efficiency for UroGen Pharma Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of UroGen Pharma Ltd from 2013 to 2025. Review how much free cash does UroGen Pharma Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-105.47 Million | $-162.44 Million | 1.540x | -85.99% |
| 2024-12-31 | $-8.80 Million | $-96.77 Million | 10.992x | +838.56% |
| 2023-12-31 | $-65.21 Million | $-76.38 Million | 1.171x | +19.53% |
| 2022-12-31 | $-89.36 Million | $-87.56 Million | 0.980x | +109.71% |
| 2021-12-31 | $8.41 Million | $-84.89 Million | -10.091x | -818.23% |
| 2020-12-31 | $96.36 Million | $-105.89 Million | -1.099x | -179.00% |
| 2019-12-31 | $180.30 Million | $-71.02 Million | -0.394x | +4.95% |
| 2018-12-31 | $90.09 Million | $-37.33 Million | -0.414x | -196.64% |
| 2017-12-31 | $68.52 Million | $-9.57 Million | -0.140x | -154.38% |
| 2016-12-31 | $16.31 Million | $4.19 Million | 0.257x | +161.41% |
| 2015-12-31 | $17.15 Million | $-7.17 Million | -0.418x | +64.76% |
| 2014-12-31 | $3.47 Million | $-4.12 Million | -1.187x | -27.26% |
| 2013-12-31 | $2.74 Million | $-2.56 Million | -0.933x | -- |
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder… Read more